Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Multiple Doses of BIIB091 on Cardiac Repolarization (QTc) in Healthy Participants
NCT06574828Phase 1Completed
- Sponsor
- Biogen
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of biib091 in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoints: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) for BIIB091 at Day 14 and Change From Baseline in QT Interval Corrected for Heart Rate (QTc) for Metabolite 23 (M23) at Day 14. Started Aug 2024; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06574828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574828.